Examining key rheumatoid arthritis patient data [whitepaper]

Rheumatoid arthritis, also known as RA, is a chronic, autoimmune disease that primarily impacts the joints. It impacts 1.5 million people in the United States, with women being three times more likely to develop the condition. While RA does not typically exhibit symptoms early on, it becomes more impactful as it progresses, causing pain, swelling, stiffness, and an eventual loss of joint function. Many patients experience fluctuating symptoms, making it difficult to predict and plan around flare-up periods.

It is currently unclear what the cause of rheumatoid arthritis is and it can begin at any age, but the risk of developing it does increase as individuals get older. There is also no known cure for the condition, so treatment plans typically involve a combination of medications, physical therapy, and sometimes surgical intervention — all of which can significantly impact a patient’s quality of life. 

Fortunately, research is ongoing to create more medical breakthroughs for rheumatoid arthritis: As of July 2023, there were more than 100 active studies focused on RA therapies. In this whitepaper, we’re using data we’ve collected from the Antidote database to explore how to recruit patients for clinical trials like these using data-driven trial design and outreach strategy. We examine the typical demographics, location, and medication usage of RA patients, and draw a throughline from these factors to improved clinical trial enrollment. To get your copy, click the link below.